In the domain of public policy on pharmaceuticals,
protecting public health requires a dual strategy: robust regulation on the one hand and stimulation of competitiveness and innovation on the other. Regulation must be robust to ensure that only
medicines meetings exacting standards of safety, quality and efficacy are authorised for human and animal use. At the same time competitiveness and innovation must be stimulated. Without innovation in pharmaceuticals, the incurable diseases of today will remain incurable. Competitiveness drives innovation and innovation saves lives. This dual strategy is also crucial in driving forward the Lisbon agenda. Increased competitiveness of the…
